Affilogic is financing a proof of concept thanks to the Boost4Health programme

31 May 2018

Affilogic,a member of Atlanpole Biotherapies, has received a € 5000 voucher as part of the Boost4Health programme. This support has enabled it to work in partnership with a unit of the Free University of Brussels (ULB), DIAPath[1], on the validation of Nanofitins®  directed against a prime target of breast, lung and colon cancers.

The aim of this partnership is to confirm the broad circulation of these Nanofitins®  within a tumour thanks to DIAPath’s experience of in vivo imaging for the chosen models.  The results of this ongoing study will allow a significant milestone to be reached in the development of anti-cancer Nanofitins®. The ability to rapidly reach the vast majority of cells within a solid tumour is actually a major issue for existing molecules, which could be resolved by this new class of molecules.

This partnership between Affilogic and DIAPath, initiated as part of the Interreg North-West Europe Boost4Health project, will continue with a more complete study and, potentially, therapeutic validations.

Affilogic is a private biotechnology company specialising in the discovery and development of Nanofitins® as biotherapies.

Nanofitins® are primarily developed:

  • As an active ingredient, for the inhibition of inflammatory pathways or the recruitment of immune cells.
  • As targeting agents for specific receptors in combination with a third-party molecule, for imaging or for Antibody Drug Conjugate type strategies.
  • To endow third-party molecules, such as antibodies or enzymes, with additional specificity.

Nanofitin®-based biotherapies are currently being developed in partnership with Sanofi, Takeda and a number of other pharmaceutical companies.

[1] DIAPath = Digital Image Analysis in Pathology